These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 9647865)

  • 1. Basic guide to the mechanisms of antiestrogen action.
    MacGregor JI; Jordan VC
    Pharmacol Rev; 1998 Jun; 50(2):151-96. PubMed ID: 9647865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
    Levenson AS; Jordan VC
    Cancer Res; 1998 May; 58(9):1872-5. PubMed ID: 9581827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    Jordan VC; O'Malley BW
    J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
    Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS; Parker CJ; McCague R; Jordan VC
    Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy.
    O'Regan RM; England GM; Macgregor JI; Yao KA; Muenzner HD; Takei H; Jordan VC
    Breast Cancer; 1998; 5(3):211-7. PubMed ID: 18841334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
    Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The estrogen receptor: a model for molecular medicine.
    Jensen EV; Jordan VC
    Clin Cancer Res; 2003 Jun; 9(6):1980-9. PubMed ID: 12796359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene and its role in breast cancer prevention.
    Eng-Wong J; Zujewski JA
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):523-32. PubMed ID: 15270657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
    Leclercq G; Devleeschouwer N; Heuson JC
    J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.
    Lerner LJ; Jordan VC
    Cancer Res; 1990 Jul; 50(14):4177-89. PubMed ID: 2194650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Estrogen receptor and selective estrogen receptor modulators (SERMs)].
    Shioi A; Nishizawa Y
    Nihon Rinsho; 1999 May; 57(5):1199-207. PubMed ID: 10361456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiestrogen pharmacology and mechanism of action.
    Katzenellenbogen BS; Miller MA; Eckert RL; Sudo K
    J Steroid Biochem; 1983 Jul; 19(1A):59-68. PubMed ID: 6887873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of estradiol, raloxifene and tamoxifen on estrogen receptor expression in cultured human skin fibroblasts.
    Haczynski J; Tarkowski R; Jarzabek K; Wolczynski S; Magoffin DA; Czarnocki KJ; Ziegert M; Jakowicki J; Jakimiuk AJ
    Int J Mol Med; 2004 Jun; 13(6):903-8. PubMed ID: 15138633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptors in human myeloma cells.
    Otsuki T; Yamada O; Kurebayashi J; Moriya T; Sakaguchi H; Kunisue H; Yata K; Uno M; Yawata Y; Ueki A
    Cancer Res; 2000 Mar; 60(5):1434-41. PubMed ID: 10728710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.